

Data Sheet

NAME: TRO, clone 11 (SVPB12)

REPOSITORY REFERENCE: **ARP2058**

NOTE: This clone is also available as a member of a panel set, see **ARP2066**

PROVIDED: 20 µg of plasmid DNA in TE buffer (0.5 mg/ml)

HOST STRAIN: TRO

CLONING SITE: The HIV-1 env/rev cassette was directly cloned into the cloning site of pcDNA3.1D/V5-His TOPO© expression vector, in the correct orientation with the CMV promoter. The size of the insert is 3121 bp.

CLONING VECTOR: pcDNA3.1D/V5-His TOPO©. The size of the cloning vector including the insert is 8635 bp.

DESCRIPTION: A PCR fragment containing full-length env and rev genes was derived from the genomic DNA of infected PBMC. Original virus was obtained by PBMC co-culture. The env/rev cassette was cloned into pcDNA3.1D/V5-His TOPO© expression vector by a directional cloning approach. A single transformed ampicillin resistant *E. coli* colony was selected and expanded. Recombinant plasmid carries resistance genes for ampicillin and neomycin.

SPECIAL CHARACTERISTICS: The clone represents env/rev sequences from a subject with acute subtype B infection (male-male transmission in Italy). The clone expresses a functional env/rev cassette and can be used to generate pseudotyped infectious virions that use CCR5 as the viral co-receptor. TRO.11 Env containing pseudovirions are included in a standard virus neutralization panel for subtype B strains (SVPB12).

PLASMID EXPANSION:

It is recommended that this plasmid be expanded using DH5 α TM Competent Cells in LB medium at 34°C.

GENE BANK:

Accession number is AY835445

STORAGE:

-80°C

SOURCE:

Dr. David Montefiori, Dr. Feng Gao and Dr. Ming Li.
(Courtesy of NIH AIDS Research and Reference Reagent Programme.)

REFERENCE :

Li, M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. *J. Virology* **79**(16): 10108-10124, 2005.

ACKNOWLEDGEMENTS:

Publications should acknowledge the donor of the reagent and the Programme EVA Centre for AIDS Reagents. Suggested wording can be found on our website at <http://www.nibsc.ac.uk/spotlight/aidsreagent/index.html> in the “Acknowledgements” section.

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR (this can be electronically or as a paper copy)